Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1.

Division of Gastroenterology, Dana-Farber Cancer Institute, and Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA. sapna_syngal@dfci.harvard,edu
Journal of Medical Genetics (Impact Factor: 5.64). 10/2000; 37(9):641-5.
Source: PubMed

ABSTRACT There are multiple criteria for the clinical diagnosis of hereditary non-polyposis colorectal cancer (HNPCC). The value of several of the newer proposed diagnostic criteria in identifying subjects with mutations in HNPCC associated mismatch repair genes has not been evaluated, and the performance of the different criteria have not been formally compared with one another.
We classified 70 families with suspected hereditary colorectal cancer (excluding familial adenomatous polyposis) by several existing clinical criteria for HNPCC, including the Amsterdam criteria, the Modified Amsterdam criteria, the Amsterdam II criteria, and the Bethesda criteria. The results of analysis of the mismatch repair genes MSH2 and MLH1 by full gene sequencing were available for a proband with colorectal neoplasia in each family. The sensitivity and specificity of each of the clinical criteria for the presence of MSH2 and MLH1 mutations were calculated.
Of the 70 families, 28 families fulfilled the Amsterdam criteria, 39 fulfilled the Modified Amsterdam Criteria, 34 fulfilled the Amsterdam II criteria, and 56 fulfilled at least one of the seven Bethesda Guidelines for the identification of HNPCC patients. The sensitivity and specificity of the Amsterdam criteria were 61% (95% CI 43-79) and 67% (95% CI 50-85). The sensitivity of the Modified Amsterdam and Amsterdam II criteria were 72% (95% CI 58-86) and 78% (95% CI 64-92), respectively. Overall, the most sensitive criteria for identifying families with pathogenic mutations were the Bethesda criteria, with a sensitivity of 94% (95% CI 88-100); the specificity of these criteria was 25% (95% CI 14-36). Use of the first three criteria of the Bethesda guidelines only was associated with a sensitivity of 94% and a specificity of 49% (95% CI 34-64).
The Amsterdam criteria for HNPCC are neither sufficiently sensitive nor specific for use as a sole criterion for determining which families should undergo testing for MSH2 and MLH1 mutations. The Modified Amsterdam and the Amsterdam II criteria increase sensitivity, but still miss many families with mutations. The most sensitive clinical criteria for identifying subjects with pathogenic MSH2 and MLH1 mutations were the Bethesda Guidelines; a streamlined version of the Bethesda Guidelines may be more specific and easier to use in clinical practice.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Colorectal cancer (CRC), a relatively frequent tumor in industrialized countries, occurs as a result of several genetic changes. Microsatellite instability (MSI) is a molecular feature that facilitates acquisition of new mutations. MSI caused by alterations in mismatch repair (MMR) genes, genes responsible for repairing DNA mismatches caused by slippage of DNA polymerase, is observed in fifteen percent of CRCs. Lynch syndrome, the most common hereditary colon cancer-genetic syndrome, is responsible for up to 5 % of CRCs and has MSI as a characteristic. When CRC occurs, MSI testing is an important step in identifying patients with Lynch syndrome. Diagnosis of Lynch syndrome has medical implications for both the affected individual and his or her family members. In addition, MSI is a prognostic and predictive factor for cancer patients. As MSI and immunostaining of MMR proteins, which seem to be similar and complementary to MSI, become widely available in pathology laboratories, use of these tests for any newly diagnosed CRC will be an option worth considering. In this review, we focus on the issue of universal MSI screening of all CRCs, irrespective of patient age, to identify more Lynch syndrome cases than are identified by well-established clinical criteria alone. We describe the growing literature in this field and discuss the potential effects of this approach on both the individual and the health-care system.
    Current Colorectal Cancer Reports 03/2014; 10(1):27-35. DOI:10.1007/s11888-013-0204-3
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The extensive study of genetic alterations in colorectal cancer (CRC) has led to molecular diagnostics playing an increasingly important role in CRC diagnosis and treatment. Currently, it is believed that CRC is a consequence of the accumulation of both genetic and epigenetic genomic alterations. It is known that there are at least 3 major pathways that lead to colorectal carcinogenesis: (1) the chromosomal instability pathway, (2) the microsatellite instability pathway, and (3) the cytosine-phospho-guanine island methylator phenotype pathway. With recent advances in CRC genetics, the identification of specific molecular alterations responsible for CRC pathogenesis has directly influences clinical care. Patients at high risk for developing CRC can be identified by genetic testing for specific molecular alterations, and the use of molecular biomarkers for predictive and prognostic purposes is also increasing. This is clearly supported by the recent advances in genetic testing for CRC whereby specific molecular alterations are identified for the purpose of guiding treatment with targeting therapies such as anti-endothelial growth factor receptor monoclonal antibodies.
    07/2014; 12(3):184-93. DOI:10.5217/ir.2014.12.3.184
  • [Show abstract] [Hide abstract]
    ABSTRACT: Evaluate effects of a Lynch syndrome universal screening protocol in newly diagnosed endometrial cancers on subsequent genetic counseling (GC) and germline testing (GT) referral and acceptance rates.


Available from